Coronary disease & ACSResearch article
P2Y12 Inhibitor Monotherapy Combined With Colchicine Following Percutaneous Coronary Intervention (PCI) in Acute Coronary Syndrome (ACS) Patients
- Single-arm pilot trial
- proof-of-concept
Authors' conclusion
In ACS patients undergoing PCI, it is feasible to discontinue aspirin therapy and administer low-dose colchicine on the day after PCI in addition to ticagrelor or prasugrel P2Y12 inhibitors.
Study context
- Population
- ACS patients treated with drug-eluting stents190 (95.0%) completed 3-month follow-up
- Participants
- 200 patients
- Outcome
- Any stent thrombosis
- Follow-up
- 3 months
Main finding
As reported in the abstract
Any stent thrombosis (1 definite, 1 probable)
2 patients (1.0%)
Secondary outcomes
Platelet reactivity (VerifyNow) before discharge
- Platelet reactivity overall
- 27 ± 42 P2Y12 reaction units
- High platelet reactivity (>208 P2Y12 reaction units)
- 1 patient
High-sensitivity C-reactive protein (hs-CRP) · 24 hours after PCI to 1 month
- hs-CRP at 24 hours after PCI, median (IQR)
- 6.1 mg/L (IQR: 2.6-15.9 mg/L)
- hs-CRP at 1 month, median (IQR)
- 0.6 mg/L (IQR: 0.4-1.2 mg/L)
- Change from 24 hours to 1 month
- P < 0.001
High-inflammation criteria (hs-CRP ≥2 mg/L) · 24 hours after PCI to 1 month
- Prevalence decreased from 81.8% to 11.8%
- P < 0.001
Original publication
P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients. JACC Cardiovasc Interv. Published 14 August 2023. doi:10.1016/j.jcin.2023.05.035
Summarised from the published abstract; every number is checked against it